PearlMatrix Bone Graft
Cerapedics, Inc. · Decision date Jun 18, 2025
What did the FDA approve?
FDA records P240001 as an original PMA application. The recorded decision is approval, dated Jun 18, 2025.
FDA approval order statement
PearlMatrix Bone Graft is indicated for intervertebral body fusion of the spine in skeletally mature patients. PearlMatrix Bone Graft is intended to be used in conjunction with a PEEK TLIF Fusion Device and supplemental internal spinal fixation systems cleared by the FDA for use in the lumbosacral spine. The system is to be used in patients who have had at least six months of non-operative treatment. PearlMatrix Bone Graft is intended for use at one level in the lumbar spine (L2-S1) for the treatment of degenerative disc disease (DDD) with up to Grade I spondylolisthesis. DDD is defined as back and/or radicular pain of discogenic origin with degeneration of the disc confirmed by history, physical exam, and radiographic studies.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Orthopedic
- Decision date
- Jun 18, 2025
Regulatory record facts
- Identifier
- P240001
- Regulatory pathway
- Premarket approval application
- Applicant
- Cerapedics, Inc.
- Product code
- NOX
- Decision code
- APPR
- Decision date
- Jun 18, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Filler, bone void, synthetic peptide.
- Applicant
- Cerapedics, Inc.
- Product code
- NOX
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P240001 received
Application receipt date recorded by FDA.
P240001 · FDA decision
APPR
P240001/S003 · Related supplement
PearlMatrixTM Peptide Enhanced Bone Graft
Timeline entries are records held by MedtechLedger for P240001. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240001
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PearlMatrixTM Peptide Enhanced Bone GraftP240001/S003 | Cerapedics, Inc. | PMA supplement | Sep 16, 2026 | FDA |
Explore the linked device profile
Other records with product code NOX
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
i-F ACTOR Peptide Enhanced Graft SubstituteP140019/S014 | Cerapedics, LLC | PMA supplement | Sep 16, 2026 | FDA |
| Cerapedics, LLC | PMA approval | Nov 3, 2015 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cerapedics, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 11025 Dover St., Suite 1600, Westminster, CO, 80021
Sources and methodology
- Original FDA record: P240001
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
